WIRE — Pakistan faces a critical shortage of over 100 essential medicines, including life-saving drugs. Delayed price revisions by the Drug Regulatory Authority of Pakistan are disrupting production. Rising costs of raw materials and currency depreciation have impacted manufacturing expenses significantly. This situation is creating space for counterfeit and substandard products in the market. Industry representatives urge the government to approve pending hardship pricing cases immediately.
"We aggregate wires to encourage regional discovery, sending readers directly back to the original source to explore full coverage."
This is a normalized overview of the breaking feed event. The complete, official release detailing all points, background context, and statements remains hosted by the original publisher.